Whittaker Hannah, Adamson Alexander, Stone Philip, Olubori Precious, Calvert James, Dodd James, Sinha Ian, Hickman Katherine, Singh Sally, Quint Jennifer K
School of Public Health, Imperial College London, London, UK
School of Public Health, Imperial College London, London, UK.
BMJ Open Respir Res. 2025 Mar 17;12(1):e002808. doi: 10.1136/bmjresp-2024-002808.
Asthma and chronic obstructive pulmonary disease (COPD) outcomes vary by sex. We investigated whether males and females with asthma or COPD are managed differently in-hospital when admitted for an exacerbation.
Data from the National Asthma and COPD Audit Programme were used to determine three cohorts of people hospitalised for an exacerbation: (1) adults with asthma, (2) children and young people (CYP) with asthma, and (3) adults with COPD. Outcomes included the following in-hospital interventional measures: spirometry recording, respiratory specialist review, respiratory medication administration and discharge bundle recording. Linked hospital data were used to determine 30-day and 90-day readmissions and Office for National Statistics data for 90-day mortality. Random effects logistic regression was used to investigate the association between sex and in-hospital outcomes, readmission and mortality.
16 370 adults with asthma, 7156 CYP with asthma and 28 354 adults with COPD were included. Female adults with asthma had higher odds of being seen by a respiratory specialist (OR 0.1.13, 1.02-1.26) and higher odds of readmission within 30 and 90 days (OR 1.22, 1.10-1.37, OR 1.34, 1.23-1.46) compared with males. Female adults with COPD had higher odds of being seen by a respiratory specialist, (OR 1.10,1.02-1.19), being administered non-invasive ventilation (OR 1.18, 1.09-1.29), and receiving a discharge bundle (OR 1.07, 1.00-1.14), and lower odds of readmission within 90 days (OR 0.95, 0.90-1.01), or mortality within 90 days (OR 0.88, 0.81-0.96). Lastly, female CYP had higher odds of steroids administered within 1 hour (OR 1.13, 1.00-1.28) and higher 30-day and 90-day readmission compared with males (OR 1.21, 1.00-1.44 and 1.17, 1.03-1.34).
Sex differences in in-hospital care exist in adults COPD, which may impact readmissions and mortality; however, little to no sex differences in in-hospital care were seen in people with asthma yet females were more likely to be readmitted to hospital.
哮喘和慢性阻塞性肺疾病(COPD)的治疗结果因性别而异。我们调查了因病情加重入院时,哮喘或COPD的男性和女性在医院的治疗方式是否不同。
使用国家哮喘和慢性阻塞性肺疾病审计计划的数据,确定三组因病情加重而住院的人群:(1)成年哮喘患者,(2)儿童和青少年(CYP)哮喘患者,以及(3)成年COPD患者。结果包括以下住院干预措施:肺活量测定记录、呼吸专科医生会诊、呼吸药物给药和出院综合记录。利用关联的医院数据确定30天和90天再入院情况,并利用国家统计局数据确定90天死亡率。采用随机效应逻辑回归分析性别与住院结局、再入院和死亡率之间的关联。
纳入了16370名成年哮喘患者、7156名CYP哮喘患者和28354名成年COPD患者。与男性相比,成年女性哮喘患者接受呼吸专科医生会诊的几率更高(比值比[OR]为1.13,95%置信区间[CI]为1.02-1.26),30天和90天内再入院的几率也更高(OR分别为1.22,1.10-1.37;OR为1.34,1.23-1.46)。成年女性COPD患者接受呼吸专科医生会诊的几率更高(OR为1.10,95%CI为1.02-1.19),接受无创通气的几率更高(OR为1.18,1.09-1.29),接受出院综合记录的几率更高(OR为1.07,1.00-1.14),90天内再入院的几率更低(OR为0.95,0.90-1.01),90天内死亡的几率更低(OR为0.88,0.81-0.96)。最后,与男性相比,女性CYP在1小时内接受类固醇治疗的几率更高(OR为1.13,95%CI为1.00-1.28),30天和90天内再入院的几率也更高(OR分别为1.21,1.00-1.44;OR为1.17,1.03-1.34)。
成年COPD患者在住院治疗方面存在性别差异,这可能会影响再入院率和死亡率;然而,哮喘患者在住院治疗方面几乎没有性别差异,但女性更有可能再次入院。